Kadcyla trastuzumab emtansine: Phase III data

The open-label, international Phase III KRISTINE trial in 444 treatment-naive patients with HER2-positive, early stage breast cancer showed that neoadjuvant treatment with 3.6 mg/kg IV Kadcyla

Read the full 261 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE